Patent · US Active

Killer cell capable of efficiently and stably expressing antibody, and uses thereof

US12042515B2 · kind B2 · utility

0Cited by
1References
14Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 19, 2017
Grant dateJul 23, 2024
Priority date
Expiry dateDec 14, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/90
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided is a transgenic killer cell, the genome of which is stably integrated with a coding sequence comprising an antibody of a human Fc section, or an expression cassette of a coding sequence comprising a chimeric antigen receptor or an inhibitory or agonistic antibody, and an inverted terminal repeat sequence from a transposon at both ends. Also provided is a pharmaceutical composition comprising the transgenic killer cell, and uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.